Medy-Tox Inc Capital Reinvestment Ratio
Medy-Tox Inc capital reinvestment ratio. Medy-Tox Inc (086900) has a Capital Reinvestment Ratio of 0.34x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩19.03 Billion) in capital expenditures (₩6.46 Billion). Check Medy-Tox Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Medy-Tox Inc (2013–2024)
Capital reinvestment ratio of Medy-Tox Inc from 2013 to 2024. This chart tracks Medy-Tox Inc's Capital Reinvestment Ratio across 12 annual periods. Also explore 086900 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Medy-Tox Inc Capital Reinvestment Ratio by Year (2013–2024)
Medy-Tox Inc capital reinvestment ratio by year from 2013 to 2024. For the full cash flow conversion analysis, see cash efficiency ratio of Medy-Tox Inc.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.51x | ₩36.89 Billion | ₩18.72 Billion | ▼ -81.7% |
| 2023 | 2.77x | ₩13.52 Billion | ₩37.47 Billion | ▲ +633.7% |
| 2022 | 0.38x | ₩26.20 Billion | ₩9.90 Billion | ▼ -56.9% |
| 2021 | 0.88x | ₩19.97 Billion | ₩17.51 Billion | ▼ -40.5% |
| 2020 | 1.47x | ₩27.93 Billion | ₩41.14 Billion | ▲ +136.2% |
| 2019 | 0.62x | ₩33.70 Billion | ₩21.02 Billion | ▲ +304.2% |
| 2018 | 0.15x | ₩55.07 Billion | ₩8.50 Billion | ▼ -77.1% |
| 2017 | 0.67x | ₩56.55 Billion | ₩38.04 Billion | ▼ -74.8% |
| 2016 | 2.67x | ₩54.10 Billion | ₩144.67 Billion | ▲ +76.9% |
| 2015 | 1.51x | ₩22.37 Billion | ₩33.81 Billion | ▲ +857.5% |
| 2014 | 0.16x | ₩105.38 Billion | ₩16.64 Billion | ▼ -84.2% |
| 2013 | 1.00x | ₩16.60 Billion | ₩16.55 Billion | — |